160 related articles for article (PubMed ID: 36510622)
1. Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor.
Bernthal NM; Randall RL; Zeitlinger LN; Geiger EJ; Healey JH
Case Rep Orthop; 2022; 2022():7768764. PubMed ID: 36510622
[TBL] [Abstract][Full Text] [Related]
2. Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).
Lingamfelter M; Novaczyk ZB; Cheng EY
JBJS Essent Surg Tech; 2022; 12(2):. PubMed ID: 36741035
[TBL] [Abstract][Full Text] [Related]
3. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
4. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
[TBL] [Abstract][Full Text] [Related]
5. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
Giustini N; Bernthal NM; Bukata SV; Singh AS
Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
[TBL] [Abstract][Full Text] [Related]
6. Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations.
Vaynrub A; Healey JH; Tap W; Vaynrub M
Onco Targets Ther; 2022; 15():53-66. PubMed ID: 35046667
[TBL] [Abstract][Full Text] [Related]
7. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
[No Abstract] [Full Text] [Related]
8. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
9. Image-guided, intensity-modulated radiotherapy for the treatment of diffuse-type tenosynovial giant cell tumor of the knee: Case report and review of the literature.
Xiang X; Jiang W; Qiu C; Xiao N; Liang J
Medicine (Baltimore); 2021 Jul; 100(28):e26659. PubMed ID: 34260572
[TBL] [Abstract][Full Text] [Related]
10. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
11. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
[TBL] [Abstract][Full Text] [Related]
12. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor.
Lin F; Jacqueline Kwong W; Pan I; Ye X; Dai D; Tap W
Oncologist; 2024 Apr; 29(4):e535-e543. PubMed ID: 37874926
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
[TBL] [Abstract][Full Text] [Related]
14. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).
Tap W
Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241
[TBL] [Abstract][Full Text] [Related]
15. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
16. Midterm outcomes of 18 patients with primary intra-articular diffuse tenosynovial giant cell tumor (TGCT) of the knee treated with complete arthroscopic synovectomy and postoperative low-dose radiotherapy at a mean follow-up of 68 months.
Tie K; Wang H; Chen B; Yang X; Chen L
Arch Orthop Trauma Surg; 2023 Apr; 143(4):2121-2127. PubMed ID: 35562595
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
[TBL] [Abstract][Full Text] [Related]
18. A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.
Bernthal NM; Healey JH; Palmerini E; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Burke ZD; Geiger EJ; Spierenburg G; Laeis P; Beyerlein E; Ye X; van de Sande M
J Surg Oncol; 2022 Dec; 126(8):1520-1532. PubMed ID: 36006054
[TBL] [Abstract][Full Text] [Related]
19. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
[TBL] [Abstract][Full Text] [Related]
20. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Brahmi M; Vinceneux A; Cassier PA
Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
